GE HealthCare secures state funding for its breast screening system

MedTech & Diagnostics News: Breast cancer remains a significant health concern, with over 20,000 women diagnosed annually and one in seven women likely to face a breast cancer diagnosis in their lifetime. GE HealthCare Australia has announced that its mammography system, the Senographe Pristina, has received approval for use in the BreastScreen Victoria Program.

This approval lists the system among the modalities approved for both screening and assessment in the state program, which offers free breast screening every two years to women aged 50 to 74. Regular mammography screening is vital for early detection, significantly increasing the chances of successful treatment.

Despite its effectiveness in reducing breast cancer deaths by 19%, mammography can cause discomfort for nearly 80% of women, leading to fear and anxiety about the procedure.

Amit Yadav, Chief Executive Officer Australia & New Zealand at GE HealthCare, hopes that the Senographe Pristina’s more comfortable experience will encourage women to schedule regular mammograms, facilitating early disease detection and improving outcomes.

“We are proud to be part of the BreastScreen Victoria Program supporting its goal to reduce the impact of breast cancer and saves lives through early detection, while supporting technologist and radiologists through providing industry leading technology for the most comfortable and accurate imaging experience,” said Yadav.

The GE Senographe Pristina, designed in collaboration with radiologists, technologists, and patients, features an ergonomic, patient-centric design with a “self-compression” tool that allows women to control the level of pressure applied during the exam. This focus on comfort enables technologists to position patients effectively and efficiently, resulting in a fast and smooth 3D mammogram experience and enhanced diagnostic accuracy.

The superior diagnostic accuracy of the Senographe Pristina is attributed to its digital breast tomosynthesis (DBT) systems, which provide high-quality imaging crucial for early and accurate detection of breast cancer.

In reimagining healthcare, Health Industry Hub^TM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.